ASK REDCHAT ANYTHING ABOUT PROTALIX BIOTHERAPEUTICS INC.
Protalix BioTherapeutics Inc. (NYSE AMERICAN: PLX)
Listen to this Section
$2.00
+0.0350
(
+1.79% )
452.7K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| ELFABRIO (Pegunigalsidase alfa )(PRX-102)DetailsGenetic disorder, Rare genetic disease |
Approved |
| Elelyso® (taliglucerase alpha)DetailsGenetic disorder, Rare genetic disease |
Approved |
| PRX-115DetailsChronic refractory gout |
Phase 1 |
| Alidornase alfa (PRX-110)DetailsGenetic disorder, Rare genetic disease, Cystic fibrosis |
Failed |
| OPRX-106DetailsInflammatory disease, Bowel disorder |
Failed |
Market Data
|
| Open |
$2.00 |
| Previous Close |
$1.96 |
| Volume |
452.7K |
| Market Cap |
$157.92M |
| Day Range |
$1.94 - $2.02 |
| 52 Week Range |
$1.32 - $3.19 |
| Shares Outstanding |
80.57M |
| Change % |
+1.79% |
| Net Change |
▲ 0.0350 |
| Insider Ownership |
-0.02% |
| Exchange |
NYSE AMERICAN |
| Sector | Healthcare |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| IPO Year | 1996 |
| Country | Israel |
Insider Ownership Transactions
Total Amount Purchased:
-1,705,030.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2023-08-17 |
Sale |
-201903.00 |
Rubin Eyal |
| 2023-08-17 |
Sale |
-35115.00 |
Hayon Yael |
| 2023-08-17 |
Sale |
-187344.00 |
Naos Yaron |
SEC Filings
| Form Type |
Description |
Pages |
Date |
| 8-k |
8K-related |
14 |
Nov 13, 2025 |
| 10-q |
Quarterly Reports |
60 |
Nov 13, 2025 |
| 8-k |
8K-related |
15 |
Nov 03, 2025 |
| 8-k |
8K-related |
38 |
Oct 17, 2025 |
| 4 |
Insider transactions |
1 |
Sep 04, 2025 |
| 4 |
Insider transactions |
1 |
Sep 04, 2025 |
| 4 |
Insider transactions |
1 |
Sep 04, 2025 |
| 4 |
Insider transactions |
1 |
Sep 04, 2025 |
| 4 |
Insider transactions |
1 |
Sep 04, 2025 |
| 4 |
Insider transactions |
1 |
Sep 04, 2025 |